{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T20:20:45Z","timestamp":1793996445142,"version":"4.8.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medicina Cl\u00ednica"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.medcli.2020.03.013","type":"journal-article","created":{"date-parts":[[2020,6,26]],"date-time":"2020-06-26T09:02:38Z","timestamp":1593162158000},"page":"165-170","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Efficacy of ursodeoxycholic acid combined with prednisolone and immunosuppressant triple therapy in the treatment of refractory primary biliary cholangitis"],"prefix":"10.1016","volume":"155","author":[{"given":"Tian-Tian","family":"Yao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Dan","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gui-Qiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.medcli.2020.03.013_bib0155","first-page":"145","article-title":"Electronic address eee","volume":"67","year":"2017","journal-title":"European Association for the Study of the L. EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. J Hepatol."},{"key":"10.1016\/j.medcli.2020.03.013_bib0160","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/hep.30145","article-title":"Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases","volume":"69","author":"Lindor","year":"2019","journal-title":"Hepatology."},{"key":"10.1016\/j.medcli.2020.03.013_bib0165","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1053\/j.gastro.2005.12.029","article-title":"Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid","volume":"130","author":"Pares","year":"2006","journal-title":"Gastroenterology."},{"key":"10.1016\/j.medcli.2020.03.013_bib0170","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1053\/j.gastro.2004.11.009","article-title":"The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis","volume":"128","author":"Corpechot","year":"2005","journal-title":"Gastroenterology."},{"key":"10.1016\/j.medcli.2020.03.013_bib0175","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1056\/NEJMoa1714519","article-title":"A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis","volume":"378","author":"Corpechot","year":"2018","journal-title":"N Engl J Med."},{"key":"10.1016\/j.medcli.2020.03.013_bib0180","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1111\/liv.14165","article-title":"Additional fibrate treatment in UDCA-refractory PBC patients","volume":"39","author":"Chung","year":"2019","journal-title":"Liver Int."},{"key":"10.1016\/j.medcli.2020.03.013_bib0185","doi-asserted-by":"crossref","first-page":"e104","DOI":"10.1097\/MD.0000000000000104","article-title":"Case-control study on prednisolone combined with ursodeoxycholic acid and azathioprine in pure primary biliary cirrhosis with high levels of immunoglobulin G and transaminases: efficacy and safety analysis","volume":"93","author":"Fang","year":"2014","journal-title":"Medicine (Baltimore)."},{"key":"10.1016\/j.medcli.2020.03.013_bib0190","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1002\/hep.20646","article-title":"Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis: a three-year randomized trial","volume":"41","author":"Rautiainen","year":"2005","journal-title":"Hepatology."},{"key":"10.1016\/j.medcli.2020.03.013_bib0195","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1111\/liv.13477","article-title":"Treatment of primary biliary cholangitis ursodeoxycholic acid non-responders: A systematic review","volume":"37","author":"Suraweera","year":"2017","journal-title":"Liver Int."},{"key":"10.1016\/j.medcli.2020.03.013_bib0200","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1046\/j.1365-2036.2000.00869.x","article-title":"Multicentre randomized placebo-controlled trial of ursodeoxycholic acid with or without colchicine in symptomatic primary biliary cirrhosis","volume":"14","author":"Almasio","year":"2000","journal-title":"Aliment Pharmacol Ther."},{"key":"10.1016\/j.medcli.2020.03.013_bib0205","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/apt.13465","article-title":"Combined ursodeoxycholic acid (UDCA) and fenofibrate in primary biliary cholangitis patients with incomplete UDCA response may improve outcomes","volume":"43","author":"Cheung","year":"2016","journal-title":"Aliment Pharmacol Ther."},{"key":"10.1016\/j.medcli.2020.03.013_bib0210","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/S0168-8278(98)80254-7","article-title":"Triple therapy with ursodeoxycholic acid, prednisone and azathioprine in primary biliary cirrhosis: a 1-year randomized, placebo-controlled study","volume":"29","author":"Wolfhagen","year":"1998","journal-title":"J Hepatol."},{"key":"10.1016\/j.medcli.2020.03.013_bib0215","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1097\/00042737-199910000-00015","article-title":"Combination therapy with mycophenolate mofetil and ursodeoxycholic acid for primary biliary cirrhosis","volume":"11","author":"Jones","year":"1999","journal-title":"Eur J Gastroenterol Hepatol."},{"key":"10.1016\/j.medcli.2020.03.013_bib0220","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1097\/01.mcg.0000177230.13770.4e","article-title":"Mycophenolate mofetil for the treatment of primary biliary cirrhosis in patients with an incomplete response to ursodeoxycholic acid","volume":"39","author":"Talwalkar","year":"2005","journal-title":"J Clin Gastroenterol."},{"issue":"4\u20135","key":"10.1016\/j.medcli.2020.03.013_bib0225","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.gcb.2010.02.004","article-title":"Triple therapy with ursodeoxycholic acid, budesonide and mycophenolate mofetil in patients with features of severe primary biliary cirrhosis not responding to ursodeoxycholic acid alone","volume":"34","author":"Rabahi","year":"2010","journal-title":"Gastroenterol Clin Biol."},{"key":"10.1016\/j.medcli.2020.03.013_bib0230","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1016\/j.jhep.2011.02.031","article-title":"Early primary biliary cirrhosis: biochemical response to treatment and prediction of long-term outcome","volume":"55","author":"Corpechot","year":"2011","journal-title":"J Hepatol."},{"key":"10.1016\/j.medcli.2020.03.013_bib0235","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1053\/jhep.2003.50346","article-title":"A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C","volume":"38","author":"Wai","year":"2003","journal-title":"Hepatology."},{"key":"10.1016\/j.medcli.2020.03.013_bib0240","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1002\/hep.21178","article-title":"Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection","volume":"43","author":"Sterling","year":"2006","journal-title":"Hepatology."},{"key":"10.1016\/j.medcli.2020.03.013_bib0245","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1111\/j.1440-1746.2010.06383.x","article-title":"Simpler score of routine laboratory tests predicts liver fibrosis in patients with chronic hepatitis B","volume":"25","author":"Zhou","year":"2010","journal-title":"J Gastroenterol Hepatol."},{"key":"10.1016\/j.medcli.2020.03.013_bib0250","article-title":"Clinical utility of FibroScan as a non-invasive diagnostic test for primary biliary cholangitis","author":"Joshita","year":"2019","journal-title":"J Gastroenterol Hepatol."},{"key":"10.1016\/j.medcli.2020.03.013_bib0255","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1111\/apt.13927","article-title":"The risk predictive values of UK-PBC and GLOBE scoring system in Chinese patients with primary biliary cholangitis: the additional effect of anti-gp210","volume":"45","author":"Yang","year":"2017","journal-title":"Aliment Pharmacol Ther."},{"issue":"Suppl 2","key":"10.1016\/j.medcli.2020.03.013_bib0260","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1159\/000440761","article-title":"Therapy of Primary Biliary Cirrhosis: Novel Approaches for Patients with Suboptimal Response to Ursodeoxycholic Acid","volume":"33","author":"Pares","year":"2015","journal-title":"Dig Dis."},{"key":"10.1016\/j.medcli.2020.03.013_bib0265","doi-asserted-by":"crossref","first-page":"105","DOI":"10.3109\/13697137.2010.507888","article-title":"Hypercholesterolemia accelerates bone loss in postmenopausal women","volume":"14","author":"Tarakida","year":"2011","journal-title":"Climacteric."},{"key":"10.1016\/j.medcli.2020.03.013_bib0270","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/hep.510310209","article-title":"Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid","volume":"31","author":"Angulo","year":"2000","journal-title":"Hepatology."},{"key":"10.1016\/j.medcli.2020.03.013_bib0275","doi-asserted-by":"crossref","first-page":"745","DOI":"10.3109\/00365521.2015.1132337","article-title":"Long-term outcomes in antimitochondrial antibody negative primary biliary cirrhosis","volume":"51","author":"Juliusson","year":"2016","journal-title":"Scand J Gastroenterol."},{"key":"10.1016\/j.medcli.2020.03.013_bib0280","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1002\/hep.510250507","article-title":"Comparison of the clinical features and clinical course of antimitochondrial antibody-positive and -negative primary biliary cirrhosis","volume":"25","author":"Invernizzi","year":"1997","journal-title":"Hepatology."},{"key":"10.1016\/j.medcli.2020.03.013_bib0285","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1111\/liv.13316","article-title":"Association between serum soluble CD14 and IL-8 levels and clinical outcome in primary biliary cholangitis","volume":"37","author":"Umemura","year":"2017","journal-title":"Liver Int."},{"key":"10.1016\/j.medcli.2020.03.013_bib0290","article-title":"IgM response is a prognostic biomarker of primary biliary cholangitis treated with ursodeoxycholic acid and bezafibrate","author":"Takano","year":"2019","journal-title":"J Gastroenterol Hepatol."},{"key":"10.1016\/j.medcli.2020.03.013_bib0295","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1053\/j.gastro.2012.12.005","article-title":"Sex and age are determinants of the clinical phenotype of primary biliary cirrhosis and response to ursodeoxycholic acid","volume":"144","author":"Carbone","year":"2013","journal-title":"Gastroenterology."},{"key":"10.1016\/j.medcli.2020.03.013_bib0300","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.bpg.2018.06.004","article-title":"Improving prognosis in primary biliary cholangitis - Therapeutic options and strategy","volume":"34\u201335","author":"Harms","year":"2018","journal-title":"Best Pract Res Clin Gastroenterol."}],"container-title":["Medicina Cl\u00ednica"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775320303213?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775320303213?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T01:51:13Z","timestamp":1758419473000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025775320303213"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["S0025775320303213"],"URL":"https:\/\/doi.org\/10.1016\/j.medcli.2020.03.013","relation":{},"ISSN":["0025-7753"],"issn-type":[{"value":"0025-7753","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of ursodeoxycholic acid combined with prednisolone and immunosuppressant triple therapy in the treatment of refractory primary biliary cholangitis","name":"articletitle","label":"Article Title"},{"value":"Medicina Cl\u00ednica","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medcli.2020.03.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}